NYCE T cells

NYCE T cells are a form of autologous cell therapy in which patient-derived T cells are gene-engineered by lentiviral transduction to express a synthetic T cell receptor (TCR) targeting the cancer-testis antigen NY-ESO-1. The cells are then gene-edited using CRISPR-Cas9 technology to knock out endogenous TCR genes (TRAC and TRBC) and the immune checkpoint receptor PD-1 (PDCD1), enhancing transgenic TCR expression while promoting resistance to PD-L1/L2-mediated exhaustion. This design aims to overcome limitations such as TCR mispairing, low transgenic TCR surface expression, and checkpoint inhibition. NYCE T cells are infused following lymphodepleting chemotherapy for the treatment of relapsed/refractory NY-ESO-1-expressing cancers, primarily myeloma and sarcoma. - Mechanism of action: Adoptive transfer of T cells engineered for specific recognition of NY-ESO-1 antigen, with CRISPR editing to increase TCR function and resistance to immune suppression[1][2][3][8][9].

Brand names

NYCE T cells

Other names

NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T cellsNY-ESO-1 transduced CRISPR 3X edited cellsNY-ESO1 transduced CRISPR 3X edited cellsNY-ESO 1 transduced CRISPR 3X edited cells